These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16860138

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ, Atomoxetine Low-dose Study Group.
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
    Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, Ball SG, Spencer TJ.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):176-85. PubMed ID: 20040824
    [Abstract] [Full Text] [Related]

  • 18. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW, Earl CQ, Arora S.
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [Abstract] [Full Text] [Related]

  • 19. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.